PepCan for Head and Neck Cancers
This trial will test if seven injections of PepCan over two years can help prevent HPV-related head and neck cancers from coming back. They will also look at side effects and changes in the gut microbiome.
- Head and Neck Cancer
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2012 Phase 3 trial • 6104 Patients • NCT01346592
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Is this experiment currently searching for participants?
"Affirmative, the details available on clinicaltrials.gov indicate that this study is currently recruiting individuals for participation. The trial was first advertised in November 2019 and last revised October 2022. This experiment requires 20 test subjects from a single medical center to take part."
Could you provide the aggregate figure for participants enrolled in this clinical trial?
"Affirmative. The information on clinicaltrials.gov pronounces that recruitment for this experiment is in progress. Initially posted on November 13th 2019, the trial was last updated October 18th 2022 and aims to recruit 20 participants from a single site."
Am I eligible to join this investigation?
"This trial is seeking 20 applicants with head malignancies, ranging between 18 and 100 years of age. Essential eligibility criteria include a respiratory rate no lower than 12 nor higher than 25 breaths per minute, an ECOG performance status between 0-2, a heart rate that oscillates between 50 to 100 beats per minute, in addition to being either male or female aged over 18 years old."
Are adolescents accepted in this investigation?
"The parameters for participation in this research trial require that individuals are aged between 18 and 100 years old."
Could you please elucidate on any other investigations that have been done concerning PepCan?
"Presently, 3 clinical trials related to PepCan are ongoing. Not one of these is in its third phase; however, there are three medical centres operating studies for this treatment - all based in Little Rock, Arkansas."